

Albert Sungsoo Kim

Curriculum Vitae



Staff Specialist Endocrinologist, Clinical Senior Lecturer
Department of Endocrinology, Westmead Hospital, University of Sydney, Australia

Educational Background & Professional Experience

Academic

2026–Present	Clinical Senior Lecturer, Sydney Medical School, University of Sydney, Australia
2023–2025	Unit Coordinator, Advanced Endocrinology, Faculty of Medicine and Health, University of Sydney
2018–2022	Clinical Associate Lecturer, Sydney Medical School, University of Sydney

Clinical

2022–Present	Staff Specialist in Endocrinology, Westmead Hospital, Australia
2019–2021	Endocrinology Advanced Trainee, Westmead and Royal North Shore Hospital
2016–2018	Basic Physician Trainee, Division of Medicine, Westmead Hospital
2015	Intern, Westmead Hospital

Research Interests

Osteoporosis, Osteoclasts, Antiresorptive, Translational Research

Publications

1. Kim AS, Taylor VE, Castro–Martinez A, Dhakal S, Zamerli A, Mohanty S, Xiao Y, Simic MK, Pantalone A, Chu J, Cheng TL, Croucher PI, Center JR, Girgis CM, McDonald MM, Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa–B ligand inhibition, Journal of Bone and Mineral Research, 2025; zjaf008.
2. Kumar S, Wang M, Kim AS, Center JR, Mcdonald MM, Girgis CM. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. Journal of Bone and Mineral Research. 2025 Mar 9;zjaf037.
3. Herath M, Prince R, Munns CF, Kim AS. Hypophosphatemia across the lifespan. JBMR Plus 2025 Dec 9.
4. Kim AS, Taylor VE, Castro–Martinez A, Dhakal S, Zamerli A, Mohanty S, Xiao Y, Simic MK, Wen J, Chai R, Croucher PI, Center JR, Girgis CM, McDonald MM. Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. Journal of Bone and Mineral Research 2024; Apr;39(4):484–97.
5. Kim AS, Girgis CM, McDonald MM. Osteoclast recycling and the rebound phenomenon following withdrawal of RANKL inhibition. Current Osteoporosis Reports. 2022; 20(6): 505–515.